cddaf07a5d5131ff9f79a6cee6dd3465 pmc_25101846.pdf 492d952f9c154fcd11822344d161f0ac608527d4 pmc_25101846.pdf ea73fc70c016baddd51df3b00a8177fd3308188054d72fe0094975e2803db2b1 pmc_25101846.pdf Title: Role of Serum Cholesterol and Statin Use in the Risk of Prostate Cancer Detection and Tumor Aggressiveness Subject: The aim of this study was to analyze the relationship between statin use along with serum cholesterol levels and prostate cancer (PCa) detection and aggressiveness. Statin users of three years or more and serum cholesterol levels (SC) were assessed in 2408 men scheduled for prostate biopsy. SC was classified as normal (NSC: <200 mg/dL) or high (HSC: >200 mg/dL). High-grade PCa (HGPCa) was considered if the Gleason score was greater than 7. Statin users comprised 30.9% of those studied. The PCa detection rate was 31.2% of men on statins and 37% of non-statin users (p < 0.006). The PCa detection rate was 26.3% in men with NSC and 40.6% in those with HSC (p < 0.001). In the subset of NSC men, the PCa rate was 26.5% for statin users and 26.2% for non-users (p = 0.939), while in men with HSC, the PCa rate was 36.4% for statin users and 42.0% for non-statin users (p = 0.063). The HGPCa rate was 41.8% for statin users and 32.5% for non-users (p = 0.012). NSC men had a 53.8% rate of HGPCa, while the rate was only 27.6% in HSC men (p < 0.001). NSC men on statins had an HGPCa rate of 70.2%, while non-statin users had a rate of 41.2% (p < 0.001). The HGPCa rate for HSC men on statins was 18.8%, while the rate was 30.0% (p = 0.011) for non-users. Logistic regression analysis suggested that serum cholesterol levels could serve as an independent predictor of PCa risk, OR 1.87 (95% CI 1.56–2.24) and HGPCa risk, OR 0.31 (95% CI 0.23–0.44), while statin usage could not. Statin treatment may prevent PCa detection through serum cholesterol-mediated mechanisms. A disturbing increase in the HGPCa rate was observed in statin users who normalized their serum cholesterol. Keywords: statins; cholesterol; prostate cancer risk; prostate cancer aggressiveness Author: Juan Morote, Anna Celma, Jacques Planas, José Placer, Inés de Torres, Mireia Olivan, Juan Carles, Jaume Reventós and Andreas Doll Creator: PScript5.dll Version 5.2.2 Producer: Acrobat Distiller 10.0.0 (Windows) CreationDate: Wed Aug 6 02:53:13 2014 CEST ModDate: Wed Aug 6 02:55:20 2014 CEST Tagged: no UserProperties: no Suspects: no Form: none JavaScript: no Pages: 9 Encrypted: no Page size: 595 x 842 pts (A4) Page rot: 0 File size: 712463 bytes Optimized: no PDF version: 1.4 name type encoding emb sub uni object ID ------------------------------------ ----------------- ---------------- --- --- --- --------- BEAAEA+TimesNewRoman,Italic TrueType WinAnsi yes yes no 63 0 BEAAEC+TimesNewRoman TrueType WinAnsi yes yes no 64 0 BEAAEE+TimesNewRoman,Bold TrueType WinAnsi yes yes no 65 0 BEAAKE+TimesNewRoman,BoldItalic TrueType WinAnsi yes yes no 42 0 BEAAPE+ArialNarrow TrueType WinAnsi yes yes no 47 0 BEAAED+TimesNewRoman,Bold CID TrueType Identity-H yes yes yes 46 0 BEAAPD+ArialNarrow CID TrueType Identity-H yes yes yes 45 0 BEAAEB+TimesNewRoman CID TrueType Identity-H yes yes yes 48 0 BEABEE+Arial TrueType WinAnsi yes yes no 49 0 Jhove (Rel. 1.22.1, 2019-04-17) Date: 2020-08-10 13:53:31 CEST RepresentationInformation: pmc_25101846.pdf ReportingModule: PDF-hul, Rel. 1.12.1 (2019-04-17) LastModified: 2018-01-29 05:46:28 CET Size: 712463 Format: PDF Version: 1.4 Status: Well-Formed and valid SignatureMatches: PDF-hul MIMEtype: application/pdf Profile: ISO PDF/A-1, Level B PDFMetadata: Objects: 88 FreeObjects: 2 IncrementalUpdates: 2 DocumentCatalog: PageLayout: SinglePage PageMode: UseThumbs Info: Title: Role of Serum Cholesterol and Statin Use in the Risk of Prostate Cancer Detection and Tumor Aggressiveness Author: Juan Morote, Anna Celma, Jacques Planas, José Placer, Inés de Torres, Mireia Olivan, Juan Carles, Jaume Reventós and Andreas Doll Subject: The aim of this study was to analyze the relationship between statin use along with serum cholesterol levels and prostate cancer (PCa) detection and aggressiveness. Statin users of three years or more and serum cholesterol levels (SC) were assessed in 2408 men scheduled for prostate biopsy. SC was classified as normal (NSC: <200 mg/dL) or high (HSC: >200 mg/dL). High-grade PCa (HGPCa) was considered if the Gleason score was greater than 7. Statin users comprised 30.9% of those studied. The PCa detection rate was 31.2% of men on statins and 37% of non-statin users (p < 0.006). The PCa detection rate was 26.3% in men with NSC and 40.6% in those with HSC (p < 0.001). In the subset of NSC men, the PCa rate was 26.5% for statin users and 26.2% for non-users (p = 0.939), while in men with HSC, the PCa rate was 36.4% for statin users and 42.0% for non-statin users (p = 0.063). The HGPCa rate was 41.8% for statin users and 32.5% for non-users (p = 0.012). NSC men had a 53.8% rate of HGPCa, while the rate was only 27.6% in HSC men (p < 0.001). NSC men on statins had an HGPCa rate of 70.2%, while non-statin users had a rate of 41.2% (p < 0.001). The HGPCa rate for HSC men on statins was 18.8%, while the rate was 30.0% (p = 0.011) for non-users. Logistic regression analysis suggested that serum cholesterol levels could serve as an independent predictor of PCa risk, OR 1.87 (95% CI 1.56 2.24) and HGPCa risk, OR 0.31 (95% CI 0.23 0.44), while statin usage could not. Statin treatment may prevent PCa detection through serum cholesterol-mediated mechanisms. A disturbing increase in the HGPCa rate was observed in statin users who normalized their serum cholesterol. Keywords: statins; cholesterol; prostate cancer risk; prostate cancer aggressiveness Creator: PScript5.dll Version 5.2.2 Producer: Acrobat Distiller 10.0.0 (Windows) CreationDate: Wed Aug 06 02:53:13 CEST 2014 ModDate: Wed Aug 06 02:55:20 CEST 2014 ID: 0x298327fa2cba2ad6c68f9070210728e8, 0x8f209a8fc82338438c0ab3e5e296ded4 Filters: FilterPipeline: FlateDecode Fonts: Type0: Font: BaseFont: BEAAEB+TimesNewRoman Encoding: Identity-H ToUnicode: true Font: BaseFont: BEAAPD+ArialNarrow Encoding: Identity-H ToUnicode: true Font: BaseFont: BEAAED+TimesNewRoman,Bold Encoding: Identity-H ToUnicode: true TrueType: Font: BaseFont: BEAAEC+TimesNewRoman FontSubset: true FirstChar: 32 LastChar: 243 FontDescriptor: FontName: BEAAEC+TimesNewRoman Flags: Serif, Nonsymbolic FontBBox: -568, -307, 2000, 1007 FontFile2: true Encoding: WinAnsiEncoding Font: BaseFont: BEAAEE+TimesNewRoman,Bold FontSubset: true FirstChar: 32 LastChar: 243 FontDescriptor: FontName: BEAAEE+TimesNewRoman,Bold Flags: Serif, Nonsymbolic FontBBox: -558, -307, 2000, 1026 FontFile2: true Encoding: WinAnsiEncoding Font: BaseFont: BEABEE+Arial FontSubset: true FirstChar: 32 LastChar: 32 FontDescriptor: FontName: BEABEE+Arial Flags: Nonsymbolic FontBBox: -665, -325, 2000, 1006 FontFile2: true Encoding: WinAnsiEncoding Font: BaseFont: BEAAKE+TimesNewRoman,BoldItalic FontSubset: true FirstChar: 112 LastChar: 112 FontDescriptor: FontName: BEAAKE+TimesNewRoman,BoldItalic Flags: Serif, Nonsymbolic, Italic FontBBox: -547, -307, 1401, 1032 FontFile2: true Encoding: WinAnsiEncoding Font: BaseFont: BEAAEA+TimesNewRoman,Italic FontSubset: true FirstChar: 32 LastChar: 121 FontDescriptor: FontName: BEAAEA+TimesNewRoman,Italic Flags: Serif, Nonsymbolic, Italic FontBBox: -498, -307, 1333, 1023 FontFile2: true Encoding: WinAnsiEncoding Font: BaseFont: BEAAPE+ArialNarrow FontSubset: true FirstChar: 32 LastChar: 134 FontDescriptor: FontName: BEAAPE+ArialNarrow Flags: Nonsymbolic FontBBox: -182, -307, 1000, 1086 FontFile2: true Encoding: WinAnsiEncoding CIDFontType2: Font: BaseFont: BEAAED+TimesNewRoman,Bold CIDSystemInfo: Registry: Adobe Registry: Identity Supplement: 0 FontDescriptor: FontName: BEAAED+TimesNewRoman,Bold Flags: Serif, Symbolic FontBBox: -558, -307, 2000, 1026 FontFile2: true Font: BaseFont: BEAAPD+ArialNarrow CIDSystemInfo: Registry: Adobe Registry: Identity Supplement: 0 FontDescriptor: FontName: BEAAPD+ArialNarrow Flags: Symbolic FontBBox: -182, -307, 1000, 1086 FontFile2: true Font: BaseFont: BEAAEB+TimesNewRoman CIDSystemInfo: Registry: Adobe Registry: Identity Supplement: 0 FontDescriptor: FontName: BEAAEB+TimesNewRoman Flags: Serif, Symbolic FontBBox: -568, -307, 2000, 1007 FontFile2: true XMP: 1 B Acrobat Distiller 10.0.0 (Windows) statins; cholesterol; prostate cancer risk; prostate cancer aggressiveness PScript5.dll Version 5.2.2 2014-08-06T08:55:20+08:00 2014-08-06T08:53:13+08:00 2014-08-06T08:55:20+08:00 application/pdf Role of Serum Cholesterol and Statin Use in the Risk of Prostate Cancer Detection and Tumor Aggressiveness Juan Morote, Anna Celma, Jacques Planas, José Placer, Inés de Torres, Mireia Olivan, Juan Carles, Jaume Reventós and Andreas Doll The aim of this study was to analyze the relationship between statin use along with serum cholesterol levels and prostate cancer (PCa) detection and aggressiveness. Statin users of three years or more and serum cholesterol levels (SC) were assessed in 2408 men scheduled for prostate biopsy. SC was classified as normal (NSC: <200 mg/dL) or high (HSC: >200 mg/dL). High-grade PCa (HGPCa) was considered if the Gleason score was greater than 7. Statin users comprised 30.9% of those studied. The PCa detection rate was 31.2% of men on statins and 37% of non-statin users (p < 0.006). The PCa detection rate was 26.3% in men with NSC and 40.6% in those with HSC (p < 0.001). In the subset of NSC men, the PCa rate was 26.5% for statin users and 26.2% for non-users (p = 0.939), while in men with HSC, the PCa rate was 36.4% for statin users and 42.0% for non-statin users (p = 0.063). The HGPCa rate was 41.8% for statin users and 32.5% for non-users (p = 0.012). NSC men had a 53.8% rate of HGPCa, while the rate was only 27.6% in HSC men (p < 0.001). NSC men on statins had an HGPCa rate of 70.2%, while non-statin users had a rate of 41.2% (p < 0.001). The HGPCa rate for HSC men on statins was 18.8%, while the rate was 30.0% (p = 0.011) for non-users. Logistic regression analysis suggested that serum cholesterol levels could serve as an independent predictor of PCa risk, OR 1.87 (95% CI 1.56–2.24) and HGPCa risk, OR 0.31 (95% CI 0.23–0.44), while statin usage could not. Statin treatment may prevent PCa detection through serum cholesterol-mediated mechanisms. A disturbing increase in the HGPCa rate was observed in statin users who normalized their serum cholesterol. statins cholesterol prostate cancer risk prostate cancer aggressiveness uuid:37f5eeee-6e12-47af-8d10-3d51598e976b uuid:9bcf87ac-8462-4882-902e-d7655b5e1590 Pages: Page: Label: 1 Page: Label: 2 Page: Label: 3 Page: Label: 4 Page: Label: 5 Page: Label: 6 Page: Label: 7 Page: Label: 8 Page: Label: 9 Checksum: 20cda7a7 Type: CRC32 Checksum: cddaf07a5d5131ff9f79a6cee6dd3465 Type: MD5 Checksum: 492d952f9c154fcd11822344d161f0ac608527d4 Type: SHA-1